Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02973113 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | ||
| NCT02276820 | Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) | ||
| NCT01570283 | ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus | ||
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma | ||
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | ||
| NCT00058786 | Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells | ||
| NCT00609219 | T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | ||
| NCT00056966 | Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases | ||
| NCT00057005 | Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation | ||
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | ||
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme | ||
| NCT00953420 | Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes | ||
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL | ||
| NCT00062855 | Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma | ||
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). | ||
| NCT00586274 | Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT | ||
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | ||
| NCT01192555 | Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma | ||
| NCT00224354 | Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells | ||
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | ||
| NCT02475707 | Administration of Donor MultiTAA-Specific T Cells for ALL | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | ||
| NCT01774097 | Patients With Intermittent Claudication Injected With ALDH Bright Cells | ||
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | ||
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT01247701 | Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies | ||
| NCT01189786 | Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection | ||
| NCT00058604 | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | ||
| NCT00840853 | Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT | ||
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | ||
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | ||
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | ||
| NCT02065362 | TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | ||
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | ||
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | ||
| NCT02239861 | TAA-Specific CTLS for Solid Tumors (TACTASOM) | ||
| NCT00040469 | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | ||
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients | ||
| NCT00579137 | Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders | ||
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | ||
| NCT01945619 | Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) | ||
| NCT02379520 | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | ||
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | ||
| NCT03690011 | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | ||
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT04715191 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors |
